Skip to main content
NewslettersWatchlist

Evolus Inc(EOLS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low13.30
Day High13.82
Open:13.74
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Why Shares of Evolus Are Jumping Thursday
Motley Fool
Twitter Faces Threats From AI and Threads
Business Wire
Evolus to Report First Quarter 2023 Results and Provide Business Update
Business Wire
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Business Wire
Evolus to Participate in the Barclays Global Healthcare Conference
Business Wire
Evolus Initiates Nuceiva® Launch in Germany and Austria
Business Wire
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
Business Wire
Evolus Not Affected by Recent Korean Court Ruling
Business Wire
Evolus to Participate in the SVB Securities Global Biopharma Conference
Business Wire
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
Business Wire
Evolus Receives Regulatory Approval for Nuceiva® in Australia
Business Wire
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
Motley Fool
Why Evolus Shares Jumped This Week
Business Wire
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
Business Wire
Evolus Extends Term of Credit Facility with Pharmakon Advisors
PR Newswire
Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc.
Business Wire
Evolus Reports Third Quarter 2022 Results and Provides Business Update
Business Wire
Evolus to Participate in November Conferences
Business Wire
Evolus to Report Third Quarter 2022 Results and Provide Business Update
Business Wire
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain
Business Wire
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022
Business Wire
Evolus Announces Inducement Grants for New Chief Financial Officer
Business Wire
Evolus Appoints Sandra Beaver as Chief Financial Officer
Business Wire
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Business Wire
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®
Business Wire
Evolus Reports Second Quarter 2022 Results and Provides Business Update
Business Wire
Evolus to Report Second Quarter 2022 Results and Provide Business Update
Business Wire
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
Business Wire
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
Business Wire
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
Business Wire
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
Business Wire
Evolus to Participate in the H.C. Wainwright Global Investment Conference

Profile

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.